The U.S. inflammatory bowel disease treatment market size is anticipated to reach USD 14.1 billion by 2030 and is projected to grow at a CAGR of 2.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of ulcerative colitis and Crohn’s disease across the U.S. is anticipated to drive market growth in the forecast period. A combination of genetic predisposition, immune system dysfunction, environmental factors, gut microbiota imbalance, and lifestyle factors likely influence the development of inflammatory bowel disease (IBD). According to an article published in 2023, inflammatory bowel disease is a relatively common chronic condition affecting >0.7% of Americans and is most prevalent in the Northeastern region. This growing patient population necessitates advanced treatment options, driving the market growth.
U.S. Inflammatory Bowel Disease Treatment Market Report Highlights
- Based on type, the Crohn’s disease segment dominated the market in 2023 with the largest revenue share. This large share is due to the requirement for more treatment options and advancements due to the chronic inflammatory nature of Crohn’s disease, which affects the gastrointestinal tract and causes symptoms such as abdominal pain, diarrhea, weight loss, and fatigue.
- On the other hand, the ulcerative colitis segment is expected to register the fastest CAGR during the forecast period, owing to its increasing incidence rate.
- Based on drug class, the TNF inhibitors segment accounted for the largest market revenue share in 2023 due to their effectiveness in managing the symptoms and reducing inflammation.
- Based on route of administration, the injectable segment held the largest market share in 2023. Injectable medications, such as biologics and biosimilars, are designed to target specific proteins or cells involved in the inflammatory process of inflammatory bowel disease.
For More Details or Sample Copy please visit link @: U.S. Inflammatory Bowel Disease Treatment Market Report
The Crohn's & Colitis Foundation works toward enhancing product development to improve the quality of life of patients suffering from inflammatory bowel illnesses. The foundation has launched these ventures, a dedicated funding system to support product-oriented research and development.
In September 2023, Takeda announced the FDA's acceptance of the biologics license application (BLA) for the subcutaneous administration of ENTYVIO (vedolizumab) to treat Crohn’s disease. Regulatory approvals pave the way for new medications, biologics, and devices to enter the market. This can lead to a broader range of treatment options for patients with IBD, potentially improving treatment outcomes and quality of life.
List of Key Companies in U.S. Inflammatory Bowel Disease (IBD) Treatment Market
- Biogen
- Novartis AG
- Eli Lilly and Company
- UCB S.A.
- Celltrion Inc.
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc
We have segmented the U.S. inflammatory bowel disease treatment market based on type, drug class, route of administration, distribution channel, and region:
U.S. IBD Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)
- Crohn's Disease
- Ulcerative Colitis
U.S. IBD Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- Aminosalicylates
- Corticosteroids
- TNF inhibitors
- IL inhibitors
- Anti-integrin
- JAK inhibitors
- Others
U.S. IBD Treatment Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Oral
- Injectable
U.S. IBD Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
U.S. IBD Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)
- West
- Midwest
- Northeast
- Southwest
- Southeast
Research Methodology
We employ a comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecasts possible. We utilize a combination of bottom-up and top-down approaches for segmenting and estimating quantitative aspects of the market. Data is continuously filtered to ensure that only validated and authenticated sources are considered. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. Our market estimates and forecasts are derived through simulation models. A unique model is created and customized for each study. Gathered information for market dynamics, technology landscape, application development, and pricing trends are fed into the model and analyzed simultaneously.
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S. based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
Contact:
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll-Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: grandviewresearch.com
#InflammatoryBowelDisease #IBDTreatment #CrohnsDisease #UlcerativeColitis #Gastroenterology #ChronicDisease #IBDCare #IBDMarket #USHealthcare #PharmaTrends #MedicalInnovation #HealthcareIndustry #MarketAnalysis #Biopharma #LifeSciences
Comments
Post a Comment